stepwise pharmacotherapy

PreclinicalSmall molecule

CChonnam National University Hospital

stepwise pharmacotherapy is one of 7 small molecule programs targeting CHOP. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CHOPRecruiting

CHOPPreclinical

Recruiting

Competition

Competitive Landscape

7 competitors in CHOP

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

2 2

Ellence

Pfizer

Phase 3

1 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

2 4

Rayos

RRoxane Laboratories

Phase 3

2 5

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 6

Chidamide

CChipscreen Biosciences, Ltd.

Phase 3

1 7

stepwise pharmacotherapy

CChonnam National University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

N/ARecruiting

CHOP

NCT06054321

Clinical

Trials by Indication[1]

CHOP1 trial

Psychopharmacotherapy for Depressive Patients

Recruiting·—·N/A·NCT06054321·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for stepwise pharmacotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — stepwise pharmacotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for stepwise pharmacotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chonnam National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CChonnam National University Hospital

stepwise pharmacotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

CHOP1 trial

References

Drug Info

Quick Facts

Related News